Biological intratumoral therapy for the high-grade glioma part II: vector- and cell-based therapies and radioimmunotherapy

Management of high-grade gliomas (HGGs) remains a complex challenge with an overall poor prognosis despite aggressive multimodal treatment. New translational research has focused on maximizing tumor cell eradication through improved tumor cell targeting while minimizing collateral systemic side effe...

Full description

Saved in:
Bibliographic Details
Published in:CNS oncology 2019-11, Vol.8 (3)
Main Authors: Loya, Joshua, Zhang, Charlie, Cox, Emily, Achrol, Achal S, Kesari, Santosh
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Brain cancer
Cell cycle
cell therapy
Clinical trials
Cytotoxicity
Dendritic cells
Encephalitis
enzyme/prodrug therapy
Genes
Glioma
high-grade glioma
Immune system
Immunotherapy
intratumoral delivery
Lymphocytes
oncolytic virus
radioimmunotherapy
Review
Tumor necrosis factor-TNF
Tumors
vector therapy
Vectors (Biology)
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Management of high-grade gliomas (HGGs) remains a complex challenge with an overall poor prognosis despite aggressive multimodal treatment. New translational research has focused on maximizing tumor cell eradication through improved tumor cell targeting while minimizing collateral systemic side effects. In particular, biological intratumoral therapies have been the focus of novel translational research efforts due to their inherent potential to be both dynamically adaptive and target specific. This two part review will provide an overview of biological intratumoral therapies that have been evaluated in human clinical trials in HGGs, and summarize key advances and remaining challenges in the development of these therapies as a potential new paradigm in the management of HGGs. Part II discusses vector-based therapies, cell-based therapies and radioimmunotherapy.
ISSN:2045-0907
2045-0915
DOI:10.2217/cns-2019-0002